Investigation of controlled salmeterol xinafoate and fluticasone propionate release from double molecular imprinted nanoparticles

Basit Öğe Kaydı
dc.authoridFEYZIOGLU-DEMIR, Esra/0000-0003-2012-4337
dc.contributor.authorFeyzioglu-Demir, Esra
dc.contributor.authorAkgol, Sinan
dc.date.accessioned2024-08-31T07:48:07Z
dc.date.available2024-08-31T07:48:07Z
dc.date.issued2024
dc.departmentEge Üniversitesien_US
dc.description.abstractSalmeterol xinafoate (SAM) and fluticasone propionate (FLU) are one of the drug combinations used together in the treatment of lung diseases such as asthma and chronic obstructive pulmonary disease (COPD). The aim of this study is to investigate the usability of novel dual molecular imprinted nanoparticles (poly(2-hydroxyethyl methacrylate-N-methacryloyl-(L)-alanine-N-methacryloyl-(L)-histidine) [p(HEMA-MAAL-MAH)], abbr. DMIPNPs) as a controlled drug release systems. In this study, SAM and FLU drugs were chosen as model drugs because they are used in the treatment of these diseases. DMIPNPs were prepared by surfactant-free emulsion polymerization method and characterized by scanning electron microscopy (SEM) and fourier transform infrared spectrometer (FTIR). In in vitro drug release experiments, drug release conditions were optimized. SAM and FLU release from DMIPNPs experiments were also performed in the simulated lung fluid (SLF). The amount of released SAM and FLU were found as 4.79 and 5.68 mg/g in the SLF medium at the end of 48 h, respectively. The release kinetics of SAM and FLU from DMIPNPs were calculated in the SLF medium. The release of SAM and FLU was determined to be compatible with the Higuchi release models. According to these results, these DMIPNPs, dual-template molecular imprinted nanoparticles with dual monomers, are promising materials that can be used in the controlled release of two different drugs.en_US
dc.description.sponsorshipScientific and Technological Research Council of Turkey (TUEBITAK) [2211/C]; Aliye Uster Foundation of Ege Universityen_US
dc.description.sponsorshipE. Feyzioglu-Demir was supported by The Scientific and Technological Research Council of Turkey (TUEBITAK), 2211/C National PhD Scholarship Program in the Priority Fields in Science and Technology during her doctoral studies. This study was financially supported by Aliye Uster Foundation of Ege University.Open access funding provided by the Scientific and Technological Research Council of Turkiye (TUBITAK).en_US
dc.identifier.doi10.1007/s00289-024-05299-6
dc.identifier.endpage12497en_US
dc.identifier.issn0170-0839
dc.identifier.issn1436-2449
dc.identifier.issue14en_US
dc.identifier.scopus2-s2.0-85192973725en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage12477en_US
dc.identifier.urihttps://doi.org/10.1007/s00289-024-05299-6
dc.identifier.urihttps://hdl.handle.net/11454/104674
dc.identifier.volume81en_US
dc.identifier.wosWOS:001222391400002en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofPolymer Bulletinen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240831_Uen_US
dc.subjectDual Molecular Imprinted Nanoparticlesen_US
dc.subjectSalmeterol Xinafoateen_US
dc.subjectFluticasone Propionateen_US
dc.subjectControlled Drug Releaseen_US
dc.subjectDrug Release Kineticsen_US
dc.subjectDual Templatesen_US
dc.titleInvestigation of controlled salmeterol xinafoate and fluticasone propionate release from double molecular imprinted nanoparticlesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu